
Edwards Lifesciences
Investments
18Portfolio Exits
3Funds
1Partners & Customers
5About Edwards Lifesciences
Edwards Lifesciences (NYSE: EW) develops medical equipment and devices. It designs, manufactures, and markets tissue heart valves and related repair products. The company also provides solutions in enhanced surgical recovery, clot management, infection control, anesthesia, hospital administration, annuloplasty rings, catheters, hemodynamic monitoring, and more. It was founded in 1958 and is based in Irvine, California.

Want to inform investors similar to Edwards Lifesciences about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Latest Edwards Lifesciences News
Sep 25, 2023
Search jobs 25-Sep-2023 FMI Forecasts Prosthetic Heart Valve Market to Surge to US$36.3 Billion by 2032 at an Impressive 11.4% CAGR The global market for prosthetic heart valves achieved a value of US$10.9 billion in 2021, and it is poised to reach US$12.3 billion by the close of 2022. The increasing incidence of valvular ailments, including aortic stenosis (AS), organic and ischemic (functional) mitral regurgitation, and tricuspid regurgitation, is fueling a substantial demand for prosthetic valves. Projections indicate a robust Compound Annual Growth Rate (CAGR) of 11.4% from 2022 to 2032, culminating in a total market value of US$36.3 billion by 2032. When considering end users, hospitals took the lead in the global prosthetic heart valve market in 2021, commanding an estimated revenue share exceeding 75%. This dominance is expected to persist throughout the forecast period Click Here to Access Your Visuals-Packed Report! According to Future Market Insights, an increasing prevalence of valvular heart disease (VHD) is expected to augment the growth of the global prosthetic heart valve market during the forecast period. Regulatory approval for heart valves, integration of technological advancements, and an increasing number of heart valve implantation procedures are other factors expected to influence the revenue growth of the global prosthetic heart valve market in the next 10 years. However, high costs associated with transcatheter heart valve products, procedure-related risks and complications, and product recalls are some restraints likely to hamper the growth of the global prosthetic heart valve market over the forecast period. Segmentation highlights The global prosthetic heart valve market is segmented on the basis of Product Type (Mechanical Heart Valves, Biological/Tissue Heart Valves, Transcatheter Heart Valves) and End User (Hospitals, Ambulatory Surgery Centres). The Transcatheter Heart Valves product type segment is estimated to be valued at US$ 6,069.1 Mn by 2026 end, registering a CAGR of 13.3% between 2016 and 2026 The Hospitals end user segment accounted for 74.5% market share of the global prosthetic heart valve market in 2015. Rising demand for quicker treatment options and remedies is expected to promote the revenue growth of the Hospitals segment over the forecast period Regional market projections The global prosthetic heart valve market is segmented by region into North America, Latin America Excluding Brazil, Brazil, Western Europe, Eastern Europe, Asia Pacific Excluding Japan (APEJ), and Middle East & Africa (MEA). The global prosthetic heart valve market is largely prominent in the developed regions. The North America regional market is estimated to witness the highest CAGR of 12.4% during the forecast period followed by the Western Europe regional market at 12.1%. Factors such as legislative openness and inline approval procedures are expected to contribute largely to the revenue generation potential and attractiveness of the Western Europe prosthetic heart valve market. Rising adoption of transcatheter heart valves in geriatric patients for better care is expected to fuel revenue growth in the Japan prosthetic heart valve market over the forecast period. Click for Methodology Details! Vendor insights The report on the global prosthetic heart valve market profiles some of the leading companies dominating the global prosthetic heart valve market. Top market players featured in the global prosthetic heart valve market report are Edwards Lifesciences Corporation, St. Jude Medical, Inc., Medtronic plc, Boston Scientific Corporation, Abbott Laboratories, SYMETIS, LivaNova PLC, CryoLife, Inc., Braile Biomedica, Colibri Heart Valve LLC, and JenaValve Technology, Inc. Leading market players are focussing on delivering differentiated therapies to cardiac patients and are strengthening their foothold in the global prosthetic heart valve market through strategic collaborations and acquisitions. Key competitors covered in terms of prosthetic heart valve market are Edwards Lifesciences Corporation, St. Jude Medical, Inc., Medtronic plc, Boston Scientific Corporation, Abbott Laboratories, SYMETIS, LivaNovaPLC, CryoLife, Inc., Braile Biomedica, Colibri Heart Valve, LLC, and JenaValve Technology, Inc. Key strategies adopted by most of the major players in the global prosthetic heart valve market include: product approvals and commercialisation, leveraging existing capabilities to create patient-centric technologies, briskly entering markets in emerging countries and offering the latest innovative technologies to healthcare facilities and, thus strengthening regional proficiency and addressing customer needs. New product launches, innovation and expansion are anticipated to form the core of these strategies during the forecast period. Get Ahead with Comprehensive Information – Purchase Now
Edwards Lifesciences Investments
18 Investments
Edwards Lifesciences has made 18 investments. Their latest investment was in egnite as part of their Seed on February 2, 2021.

Edwards Lifesciences Investments Activity

Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
2/10/2021 | Seed | egnite | Yes | 2 | ||
9/23/2020 | Series C - II | V-Wave | $28M | No | 2 | |
7/15/2020 | Series B | Caption Health | $53M | Yes | 5 | |
4/26/2018 | Series C | |||||
4/13/2016 | Series A - II |
Date | 2/10/2021 | 9/23/2020 | 7/15/2020 | 4/26/2018 | 4/13/2016 |
---|---|---|---|---|---|
Round | Seed | Series C - II | Series B | Series C | Series A - II |
Company | egnite | V-Wave | Caption Health | ||
Amount | $28M | $53M | |||
New? | Yes | No | Yes | ||
Co-Investors | |||||
Sources | 2 | 2 | 5 |
Edwards Lifesciences Portfolio Exits
3 Portfolio Exits
Edwards Lifesciences has 3 portfolio exits. Their latest portfolio exit was Caption Health on February 09, 2023.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
2/9/2023 | Acquired | 17 | |||
Date | 2/9/2023 | ||
---|---|---|---|
Exit | Acquired | ||
Companies | |||
Valuation | |||
Acquirer | |||
Sources | 17 |
Edwards Lifesciences Acquisitions
13 Acquisitions
Edwards Lifesciences acquired 13 companies. Their latest acquisition was Corvia Medical on March 11, 2019.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
---|---|---|---|---|---|---|
3/11/2019 | Series E+ | $108.28M | Acquired | 2 | ||
11/29/2018 | Acquired Unit | 1 | ||||
11/26/2018 | Acquired Unit | 1 | ||||
4/18/2018 | ||||||
12/6/2017 | Series B |
Date | 3/11/2019 | 11/29/2018 | 11/26/2018 | 4/18/2018 | 12/6/2017 |
---|---|---|---|---|---|
Investment Stage | Series E+ | Series B | |||
Companies | |||||
Valuation | |||||
Total Funding | $108.28M | ||||
Note | Acquired | Acquired Unit | Acquired Unit | ||
Sources | 2 | 1 | 1 |
Edwards Lifesciences Fund History
1 Fund History
Edwards Lifesciences has 1 fund, including Social Impact Investment Fund.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
---|---|---|---|---|---|
8/2/2021 | Social Impact Investment Fund | $70M | 1 |
Closing Date | 8/2/2021 |
---|---|
Fund | Social Impact Investment Fund |
Fund Type | |
Status | |
Amount | $70M |
Sources | 1 |
Edwards Lifesciences Partners & Customers
5 Partners and customers
Edwards Lifesciences has 5 strategic partners and customers. Edwards Lifesciences recently partnered with United Parcel Service on May 5, 2020.
Date | Type | Business Partner | Country | News Snippet | Sources |
---|---|---|---|---|---|
5/4/2020 | Vendor | United States | UPS - Get Report today announced as part of its longstanding relationship with Edwards Lifesciences , it continues to help the med-tech company get necessary equipment to hospitals around the world in the ongoing battle against COVID-19 . | 3 | |
12/10/2018 | Partner | ||||
6/29/2015 | Vendor | ||||
11/24/2004 | Licensor | ||||
Licensor |
Date | 5/4/2020 | 12/10/2018 | 6/29/2015 | 11/24/2004 | |
---|---|---|---|---|---|
Type | Vendor | Partner | Vendor | Licensor | Licensor |
Business Partner | |||||
Country | United States | ||||
News Snippet | UPS - Get Report today announced as part of its longstanding relationship with Edwards Lifesciences , it continues to help the med-tech company get necessary equipment to hospitals around the world in the ongoing battle against COVID-19 . | ||||
Sources | 3 |
Edwards Lifesciences Team
15 Team Members
Edwards Lifesciences has 15 team members, including current Chief Executive Officer, Michael A. Mussallem.
Name | Work History | Title | Status |
---|---|---|---|
Michael A. Mussallem | Chief Executive Officer | Current | |
Name | Michael A. Mussallem | ||||
---|---|---|---|---|---|
Work History | |||||
Title | Chief Executive Officer | ||||
Status | Current |
Compare Edwards Lifesciences to Competitors
Sotera Wireless is committed to the development, marketing and sale of a new generation early detection surveillance monitoring system. Its flagship product, the ViSi Mobile, is designed to improve patient safety by detecting early signs of deterioration in virtually any care setting, enabling early intervention and rapid response without limiting the patient's freedom of movement
BioBeat is a medical technology company. Its remote patient monitoring (RPM) health platform includes a disposable short-term chest-monitor and a long-term wrist-monitor, both of which utilize a photoplethysmography-based (PPG) sensor to provide patient readings of various health parameters, including cuffless blood pressure, pulse rate, respiratory rate, blood oxygen saturation, temperature, stroke volume, cardiac output, and more. The company was founded in 2016 and is based in Petach Tikva, Israel.

Aktiia's technology combines common optical sensors, known for tracking heart-rate in today's wearables, and clinically validated software algorithms to measure an individual's blood pressure at the wrist. The algorithms will be embedded in non-medical third-party wearables for the preventive purpose to track blood pressure trends, as well as in Aktiia's medical grade wearable to monitor precise blood pressure values that can be used for the diagnosis and management of hypertension.

CareTaker Medical operates as a wireless patient monitor. It uses a finger cuff to measure continuous beat-by-beat blood pressure, heart rate, and other physiological parameters enabling remote patient monitoring. CareTaker Medical was founded in 2014 and is based in Charlottesville, Virginia.

KLISBio is a med-tech company. The company develops regenerative implantable products by using silk fibroins. The company leverages a silk-based technology platform to develop scaffold materials for a variety of clinical indications, such as peripheral nerve injuries, peripheral vascular diseases, bone defects, tendon tears, and situations where a sustained drug release is needed. It was founded in 2014 and is based in Milan, Italy.
Dynocardia is a biomedical device development company that has developed ViTrack, a diagnostic device that is a stand-alone, cuff-less device that allows for continuous, non-invasive blood pressure (cNIBP) measurement. ViTrack offers direct, beat-to-beat measurement of blood pressure that is wrist-wearable and mobile. The device has data-rich capabilities such as heart rate, heart rhythm, and respiratory parameters in addition to blood pressure that enables early intervention prior to acute events. The company was founded in 2018 and is based in Cambridge, Massachusetts.